Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban Bioavailability via NGT
NCT02034578Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2011
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Maximum Observed Plasma Concentration. Started Jul 2011; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02034578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034578.